1036388-63-2

Basic information

• Product Name: (E)-methyl 2-(2-(dimethylamino)vinyl)-5-nitrobenzoate
• Synonyms: (E)-methyl 2-(2-(dimethylamino)vinyl)-5-nitrobenzoate
• CAS NO: 1036388-63-2
• Molecular Weight: 250.254
• Mol File: 1036388-63-2.mol
• Article Data: 6

Chemical Properties

• CAS DataBase Reference: (E)-methyl 2-(2-(dimethylamino)vinyl)-5-nitrobenzoate(CAS DataBase Reference)
• NIST Chemistry Reference: (E)-methyl 2-(2-(dimethylamino)vinyl)-5-nitrobenzoate(1036388-63-2)
• EPA Substance Registry System: (E)-methyl 2-(2-(dimethylamino)vinyl)-5-nitrobenzoate(1036388-63-2)

Safety Data

• Hazardous Substances Data: 1036388-63-2(Hazardous Substances Data)

Upstream product

• 77324-87-9 methyl 2-methyl-5-nitrobenzoate 
• 4637-24-5 N,N-dimethyl-formamide dimethyl acetal 
• 1975-52-6 5-nitro-o-toluic acid 
• 5815-08-7 tert-Butoxybis(dimethylamino)methane 

Downstream Products

• 1036388-65-4 2-(2,4-dimethoxybenzyl)-7-nitroisoquinolin-1(2H)-one 
• 244219-94-1 1-chloro-7-nitro-isoquinoline 

Relevant articles and documents

Design, synthesis and biological evaluation of isoquinoline-based derivatives as novel histone deacetylase inhibitors

The design, synthesis and biological evaluation of a series of isoquinoline-based hydroxamic acid compounds as novel HDACs inhibitors were reported herein. A detailed SAR study showed most of the compounds displayed good to excellent inhibitory activities against HDAC1, 3, 6. The IC50 values of compound 10c against HDAC1, 3, 6 were 4.17 ± 0.11 nM, 4.00 ± 0.10 nM, 3.77 ± 0.07 nM, respectively. Most of the compounds showed great anti-proliferative activities against RPMI 8226, HCT 116 and Hep G2 cells. The IC50 values of compounds 10a-h against RPMI 8226 cancer cell proliferation were all below 1 μM. HCT 116 cell was sensitive to the compounds 10a, 10f-g and 18a with the IC50 values 0.3 μM. The active compounds 10a-d did not show inhibitory activity against hERG channel. All these evidence indicated these compounds had great potential as HDACs inhibitors for the further development.

1 -OXO-1,2-DIHYDROISOQUINOLIN-7-YL-(5-SUBSTITUTED-THIOPHEN-2-YL)-SULFONAMIDE COMPOUNDS, FORMULATIONS CONTAINING THOSE COMPOUNDS, AND THEIR USE AS AICARFT INHIBITORS IN THE TREATMENT OF CANCERS

1-Oxo-1,2-dihydroisoquinolin-7-yl-(5-substituted-thiophen-2-yl)-sulfonamide compounds, formulations containing those compounds, and their use as AICARFT inhibitors.

BICYCLIC LACTAM FACTOR VIIA INHIBITORS USEFUL AS ANTICOAGULANTS

The present invention provides novel bicyclic lactams derivatives, and analogues thereof, of Formula (I): or a stereoisomer, tautomer, pharmaceutically acceptable salt, solvate, or prodrug thereof, wherein the variables A, B, C, W, Y, Z1, Z2, Z3, Z4, R8, and R9 are as defined herein. These compounds are selective inhibitors of factor VIIa which can be used as medicaments.